{"id":1521,"date":"2018-04-18T14:56:27","date_gmt":"2018-04-18T12:56:27","guid":{"rendered":"https:\/\/www.arbios.org\/?p=1521\/"},"modified":"2018-04-23T15:54:37","modified_gmt":"2018-04-23T13:54:37","slug":"cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium","status":"publish","type":"post","link":"https:\/\/www.arbios.org\/en\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\/","title":{"rendered":"Cyclopharma enters agreement to sell its production and commercialization activities in France to Curium group"},"content":{"rendered":"<div>\n<div class=\"TitreParaph Bleu\">\n<div>\n<div class=\"TitreParaph Bleu\"><span style=\"color: #000000;\">Cyclopharma, specialized in molecular imaging solutions, is planning to divest its manufacturing assets and radiopharmaceutical drugs production and commercialization activities in France to Curium group, a world-class company specialized in the development, production and commercialization of tracers for nuclear medicine imaging.<\/span><\/div>\n<div class=\"TitreParaph Bleu\"><\/div>\n<\/div>\n<div class=\"accordion ui-accordion ui-widget ui-helper-reset\">\n<div id=\"ui-accordion-3-header-0\" class=\"EnSavoirPlusActu ui-accordion-header ui-helper-reset ui-state-default ui-accordion-icons ui-accordion-header-active ui-state-active ui-corner-top\" tabindex=\"0\">\n<p class=\"80\"><span style=\"color: #000000;\">Cyclopharma, created in 2000, based in Clermont-Ferrand (France), develops, produces and distributes diagnostic oncologic, neurologic and cardiac imaging drugs to healthcare professionals. Acquired by Denos in 2013, Cyclopharma employs more than a hundred employees, at its 7 production and R&amp;D sites in France. Today, Cyclopharma is a leader in molecular imaging, a technique which improves patients\u2019 quality of life, efficacy of treatment while reducing costs.<\/span><\/p>\n<\/div>\n<div id=\"ui-accordion-3-panel-0\" class=\"FondGris ui-accordion-content ui-helper-reset ui-widget-content ui-corner-bottom ui-accordion-content-active\">\n<div class=\"Contenu\">\n<p><span style=\"color: #000000;\">Curium was created in January 2017 by uniting IBA Molecular and Mallindkrodt Nuclear Medicine LLC and has made a stock purchase offer to acquire Cyclopharma from Denos. With this proposed acquisition, Curium intends to increase its production capabilities to provide their customers optimal access to the tracers, meeting growing product demand. Curium would integrate the acquired production facilities into their existing radiopharmaceutical manufacturing network. This enhanced network would enable the commercial production of new compounds, as well as support the development of new products.<\/span><\/p>\n<p><span style=\"color: #000000;\">Upon the completion of the offer, R&amp;D and inte<\/span>rnational activities of Cyclopharma would be transferred to a dedicated subsidiary which would be owned and managed by Denos. The subsidiary would take over Cyclopharma\u2019s current R&amp;D projects, and commercialize those molecules in France and worldwide directly or with industrial partners.<\/p>\n<p>The divestiture of the manufacturing assets and French commercial activities will allow the management and development team to focus on the new company\u2019s mission of developing and commercializing best-in-class molecular imaging and therapy drugs. The new entity would be based in both France and the United-States. The international presence will build a strong platform for developing and commercializing products.<\/p>\n<p>The first goal of the new company will be to launch EstroTep\u00ae, a new radiopharmaceutical tracer bringing an innovative approach for breast cancer diagnosis in Europe, and seek FDA clearance in the US. EstroTep\u00ae is considered by the scientific and medical community as a useful tool in the management of breast cancer.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"accordion ui-accordion ui-widget ui-helper-reset\">\n<div id=\"ui-accordion-3-panel-0\" class=\"FondGris ui-accordion-content ui-helper-reset ui-widget-content ui-corner-bottom ui-accordion-content-active\">\n<p>&nbsp;<\/p>\n<p><span style=\"color: #008000;\"><strong>Cyclopharma<\/strong><\/span><br \/>\n<span style=\"color: #008000;\"><strong>Biop\u00f4le Clermont-Limagne<\/strong><\/span><br \/>\nPhone: +33 473 632 700<br \/>\nEmail:\u00a0<a href=\"mailto:contact@cyclopharma.fr\">contact@cyclopharma.fr<\/a><br \/>\nWebsite:\u00a0<a href=\"http:\/\/cyclopharma.fr\/\">cyclopharma.fr<\/a><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cyclopharma, specialized in molecular imaging solutions, is planning to divest its manufacturing assets and radiopharmaceutical drugs production and commercialization activities in France to Curium group, a world-class company specialized in the development, production and commercialization of tracers for nuclear medicine imaging. Cyclopharma, created in 2000, based in Clermont-Ferrand (France), develops, produces and distributes diagnostic oncologic, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1549,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-1521","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cyclopharma enters agreement to sell its production and commercialization activities in France to Curium group - Arbios<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arbios.org\/en\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cyclopharma enters agreement to sell its production and commercialization activities in France to Curium group - Arbios\" \/>\n<meta property=\"og:description\" content=\"Cyclopharma, specialized in molecular imaging solutions, is planning to divest its manufacturing assets and radiopharmaceutical drugs production and commercialization activities in France to Curium group, a world-class company specialized in the development, production and commercialization of tracers for nuclear medicine imaging. Cyclopharma, created in 2000, based in Clermont-Ferrand (France), develops, produces and distributes diagnostic oncologic, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arbios.org\/en\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\/\" \/>\n<meta property=\"og:site_name\" content=\"Arbios\" \/>\n<meta property=\"article:published_time\" content=\"2018-04-18T12:56:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-04-23T13:54:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.arbios.org\/wp-content\/uploads\/2018\/04\/tep-scan.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"699\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"arbios\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"arbios\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\\\/\"},\"author\":{\"name\":\"arbios\",\"@id\":\"https:\\\/\\\/www.arbios.org\\\/#\\\/schema\\\/person\\\/d4764a06f595d90cc731f0cbaa14ba7b\"},\"headline\":\"Cyclopharma enters agreement to sell its production and commercialization activities in France to Curium group\",\"datePublished\":\"2018-04-18T12:56:27+00:00\",\"dateModified\":\"2018-04-23T13:54:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\\\/\"},\"wordCount\":382,\"image\":{\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.arbios.org\\\/wp-content\\\/uploads\\\/2018\\\/04\\\/tep-scan.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\\\/\",\"url\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\\\/\",\"name\":\"Cyclopharma enters agreement to sell its production and commercialization activities in France to Curium group - Arbios\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.arbios.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.arbios.org\\\/wp-content\\\/uploads\\\/2018\\\/04\\\/tep-scan.jpg\",\"datePublished\":\"2018-04-18T12:56:27+00:00\",\"dateModified\":\"2018-04-23T13:54:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.arbios.org\\\/#\\\/schema\\\/person\\\/d4764a06f595d90cc731f0cbaa14ba7b\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.arbios.org\\\/en\\\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.arbios.org\\\/wp-content\\\/uploads\\\/2018\\\/04\\\/tep-scan.jpg\",\"contentUrl\":\"https:\\\/\\\/www.arbios.org\\\/wp-content\\\/uploads\\\/2018\\\/04\\\/tep-scan.jpg\",\"width\":960,\"height\":699},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.arbios.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cyclopharma enters agreement to sell its production and commercialization activities in France to Curium group\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.arbios.org\\\/#website\",\"url\":\"https:\\\/\\\/www.arbios.org\\\/\",\"name\":\"Arbios\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.arbios.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.arbios.org\\\/#\\\/schema\\\/person\\\/d4764a06f595d90cc731f0cbaa14ba7b\",\"name\":\"arbios\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g\",\"caption\":\"arbios\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cyclopharma enters agreement to sell its production and commercialization activities in France to Curium group - Arbios","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arbios.org\/en\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\/","og_locale":"en_US","og_type":"article","og_title":"Cyclopharma enters agreement to sell its production and commercialization activities in France to Curium group - Arbios","og_description":"Cyclopharma, specialized in molecular imaging solutions, is planning to divest its manufacturing assets and radiopharmaceutical drugs production and commercialization activities in France to Curium group, a world-class company specialized in the development, production and commercialization of tracers for nuclear medicine imaging. Cyclopharma, created in 2000, based in Clermont-Ferrand (France), develops, produces and distributes diagnostic oncologic, [&hellip;]","og_url":"https:\/\/www.arbios.org\/en\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\/","og_site_name":"Arbios","article_published_time":"2018-04-18T12:56:27+00:00","article_modified_time":"2018-04-23T13:54:37+00:00","og_image":[{"width":960,"height":699,"url":"https:\/\/www.arbios.org\/wp-content\/uploads\/2018\/04\/tep-scan.jpg","type":"image\/jpeg"}],"author":"arbios","twitter_card":"summary_large_image","twitter_misc":{"Written by":"arbios","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arbios.org\/en\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\/#article","isPartOf":{"@id":"https:\/\/www.arbios.org\/en\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\/"},"author":{"name":"arbios","@id":"https:\/\/www.arbios.org\/#\/schema\/person\/d4764a06f595d90cc731f0cbaa14ba7b"},"headline":"Cyclopharma enters agreement to sell its production and commercialization activities in France to Curium group","datePublished":"2018-04-18T12:56:27+00:00","dateModified":"2018-04-23T13:54:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arbios.org\/en\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\/"},"wordCount":382,"image":{"@id":"https:\/\/www.arbios.org\/en\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arbios.org\/wp-content\/uploads\/2018\/04\/tep-scan.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.arbios.org\/en\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\/","url":"https:\/\/www.arbios.org\/en\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\/","name":"Cyclopharma enters agreement to sell its production and commercialization activities in France to Curium group - Arbios","isPartOf":{"@id":"https:\/\/www.arbios.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.arbios.org\/en\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\/#primaryimage"},"image":{"@id":"https:\/\/www.arbios.org\/en\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arbios.org\/wp-content\/uploads\/2018\/04\/tep-scan.jpg","datePublished":"2018-04-18T12:56:27+00:00","dateModified":"2018-04-23T13:54:37+00:00","author":{"@id":"https:\/\/www.arbios.org\/#\/schema\/person\/d4764a06f595d90cc731f0cbaa14ba7b"},"breadcrumb":{"@id":"https:\/\/www.arbios.org\/en\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arbios.org\/en\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arbios.org\/en\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\/#primaryimage","url":"https:\/\/www.arbios.org\/wp-content\/uploads\/2018\/04\/tep-scan.jpg","contentUrl":"https:\/\/www.arbios.org\/wp-content\/uploads\/2018\/04\/tep-scan.jpg","width":960,"height":699},{"@type":"BreadcrumbList","@id":"https:\/\/www.arbios.org\/en\/cyclopharma-annonce-projet-de-cession-de-activites-de-production-de-commercialisation-france-groupe-curium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.arbios.org\/en\/"},{"@type":"ListItem","position":2,"name":"Cyclopharma enters agreement to sell its production and commercialization activities in France to Curium group"}]},{"@type":"WebSite","@id":"https:\/\/www.arbios.org\/#website","url":"https:\/\/www.arbios.org\/","name":"Arbios","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arbios.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.arbios.org\/#\/schema\/person\/d4764a06f595d90cc731f0cbaa14ba7b","name":"arbios","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/edc889faeb33c603c9491f1e7966135090d534f607758d58358d3f371a6c8583?s=96&d=mm&r=g","caption":"arbios"}}]}},"_links":{"self":[{"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/posts\/1521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/comments?post=1521"}],"version-history":[{"count":7,"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/posts\/1521\/revisions"}],"predecessor-version":[{"id":1537,"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/posts\/1521\/revisions\/1537"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/media\/1549"}],"wp:attachment":[{"href":"https:\/\/www.arbios.org\/en\/wp-json\/wp\/v2\/media?parent=1521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}